#6 - Amarin (NASDAQ:AMRN)
Amarin (NASDAQ:AMRN) is a biotechnology company that saw its stock soar with the release of Vascepa, a prescription-only omega-3 fatty acid product that is designed as a supplement to diet for reducing triglyceride levels in adult patients.
Getting a product in the market was a boost to the company’s revenue as well as its stock price. But revenue is slowing. In its most recent quarter, revenue was down 37% year-over-year, and sales have been declining in the last three quarters.
To make the outlook more troublesome, Amarin is not issuing guidance for the full year and a key reason for this is the company is still assessing the effect of generic competition for Vascepa in the United States.
AMRN stock was likely a profitable trade for some investors who got in at the right time. However, with the stock down 61% for the year and no other products on the horizon, it’s okay to pass on AMRN stock.
About Amarin
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More - Current Price
- $0.55
- Consensus Rating
- Buy
- Ratings Breakdown
- 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A
